Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
New England Journal of Medicine · 16.10.2025 · 393 (15) · 1486-1497
DOI: 10.1056/nejmoa2502754 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.10.2025. Verfasst von Claire Booth und 30 weiteren Autor:innen. Beteiligte Einrichtung: University College London Great Ormond Street Institute of Child Health, London. Hauptthemen laut MEDLINE: Adenosine Deaminase, Agammaglobulinemia, Genetic Therapy, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University College London Great Ormond Street Institute of Child Health, London.
- Department of Paediatric Immunology and Gene Therapy, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, London.
- Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles.
- Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles.
- Department of Immunology, National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre, London.
- Department of Haematology, Great Ormond Street Children's Hospital, London.
ORCID-Profile: Jack Reid, Stuart Adams, Tsai-Yu Lin
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
- Intramural NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
- Doris Duke Charitable Foundation
- California Institute for Regenerative Medicine
- NINDS NIH HHS
Zitieren
APA
Booth, C., Masiuk, K., Vazouras, K., Fernandes, A., Xu-Bayford, J., Campo Fernandez, B., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., Reid, J., Gilmour, K. C., Adams, S., Alvarez Mediavilla, E., Mhaldien, L., O'Toole, G., Ahmed, R., Garabedian, E., Malech, H., …, & Kohn, D. B. (2025). Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. New England Journal of Medicine, 393(15), 1486-1497. https://doi.org/10.1056/nejmoa2502754
Vancouver
Booth C, Masiuk K, Vazouras K, Fernandes A, Xu-Bayford J, Campo Fernandez B, et al. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. New England Journal of Medicine. 2025;393(15):1486-1497. doi:10.1056/nejmoa2502754
BibTeX
@article{Booth2025,
author = {Booth, Claire and Masiuk, Katelyn and Vazouras, Konstantinos and Fernandes, Augustine and Xu-Bayford, Jinhua and Campo Fernandez, Beatriz and Roy, Sohini and Curio-Penny, Beatrice and Arnold, Jordyn and Terrazas, Dayna and Reid, Jack and Gilmour, Kimberly C and Adams, Stuart and Alvarez Mediavilla, Elena and Mhaldien, Lana and O'Toole, Grainne and Ahmed, Rima and Garabedian, Elizabeth and Malech, Harry and De Ravin, Suk See and Moore, Theodore B and De Oliveira, Satiro and Pellin, Danilo and Lin, Tsai-Yu and Dang, Thao Thi and Cornetta, Kenneth and Hershfield, Michael S and Hara, Havinder and Thrasher, Adrian J and Gaspar, H Bobby and Kohn, Donald B},
title = {Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {15},
pages = {1486--1497},
doi = {10.1056/nejmoa2502754}
}
EUVIMED